ArticleCancer science2008
Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer.
Article in Cancer science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 58 citations in OpenAlex.
- Review
- Prognostic significance of vasohibin-1 and vasohibin-2 immunohistochemical expression in gastric cancer.Surgery today · 2020Article
- The roles of vasohibin and its family members: Beyond angiogenesis modulators.Cancer biology & therapy · 2017Review
- Increased vasohibin-1 expression is associated with metastasis and poor prognosis of renal cell carcinoma patients.Laboratory investigation; a journal of technical methods and pathology · 2017Article
- MicroRNA-4530 promotes angiogenesis by targeting VASH1 in breast carcinoma cells.Oncology letters · 2017Article
- The effect of Vasohibin-1 expression and tumor-associated macrophages on the angiogenesis in vitro and in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survival.International journal of oncology · 2015Article
- A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1.Medical oncology (Northwood, London, England) · 2014Article
- Article
- Role of the vasohibin family in the regulation of fetoplacental vascularization and syncytiotrophoblast formation.PloS one · 2014Article
- Urinary and plasma levels of vasohibin-1 can predict renal functional deterioration in patients with renal disorders.PloS one · 2014Article
- In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer.Cancer science · 2013Article
- Vasohibin-1 expression is regulated by transforming growth factor-β/bone morphogenic protein signaling pathway between tumor-associated macrophages and pancreatic cancer cells.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2013Article
- The prognostic significance of vasohibin-1 expression in patients with prostate cancer.British journal of cancer · 2013Article
- Article
- The vasohibin family: a novel family for angiogenesis regulation.Journal of biochemistry · 2013Review
- The endometrial lymphatic vasculature: function and dysfunction.Reviews in endocrine & metabolic disorders · 2012Review
- Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma.Medical oncology (Northwood, London, England) · 2012Article
- Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs.Medical oncology (Northwood, London, England) · 2012Article
- Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery.Medical oncology (Northwood, London, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have previously reported on vasohibin as a novel endothelium-derived vascular endothelial growth factor (VEGF)-inducible inhibitor of angiogenesis. The aim of our present study was to define the role of vasohibin in endometrioid endometrial adenocarcinoma. We collected 78 sections of endometrial carcinoma for assessment using immunohistochemistry. Twenty-seven were well differentiated (G1), 25 were moderately differentiated (G2), and 26 were poorly differentiated endometrioid adenocarcinomas (G3). We also included 12 sections of normal cyclic endometria, six of which were in the proliferative phase and six were in the secretory phase. We investigated the expression of vasohibin, and compared it to VEGF receptor-2 (VEGFR-2: KDR/flk-1), CD34, Ki-67, VEGF-A, and D2-40 (as a lymphatic vessel marker). We assessed the ratio of vasohibin- and VEGFR-2-positive vessels in the stroma of endometrial carcinoma. Immunohistochemical assessment was classified as negative or positive based on staining intensity. Vasohibin was selectively expressed on vascular endothelial cells in both cyclic endometria and endometrial carcinomas. Vasohibin was highly expressed in the normal functional endmetrium of the secretory phase, especially in the spiral artery, and was highly expressed in all grades of endometrioid adenocarcinomas. The stromal endothelial cells in G3 expressed vasohibin and VEGFR-2 more frequently than these in G1. In endometrioid adenocarcinomas, there was a significant correlation between the expression percentage of vasohibin and that of VEGFR-2 (P < 0.0001, r(2) = 0.591). This is the first study to elucidate the correlation between expression of vasohibin in the stromal endothelial cells and that of VEGFR-2 in human carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.